Phytoceramide ameliorates ß-amyloid protein-induced memory impairment and neuronal death in mice

Arch Pharm Res. 2017 Jun;40(6):760-771. doi: 10.1007/s12272-017-0893-2. Epub 2017 Jun 9.

Abstract

The present study was performed to investigate the protective effect of phytoceramide against ß-amyloid protein (Aβ) (25-35)-induced memory impairment and its underlying mechanisms in mice. Memory impairment in mice was induced by intracerebroventricular injection of 15 nmol Aβ (25-35) and measured by the passive avoidance test and Morris water maze test. Chronic administration of phytoceramide (10, 25 and 50 mg/kg, p.o.) resulted in significantly less Aβ (25-35)-induced memory loss and hippocampal neuronal death in treated mice compared to controls. The decrease of glutathione level and increase of lipid peroxidation in brain tissue following injection of Aβ (25-35) was reduced by phytoceramide. Alteration of apoptosis-related proteins, increase of inflammatory factors, and phosphorylation of mitogen activated proteins kinases (MAPKs) in Aβ (25-35)-administered mice hippocampus were inhibited by phytoceramide. Phosphatidylinositol 3'-kinase (PI3K)/Akt pathway and phosphorylation of cyclic AMP response element-binding protein (CREB) were suppressed, while phosphorylation of tau (p-tau) was increased in Aß (25-35)-treated mice brain; these effects were significantly inhibited by administration of phytoceramide. These results suggest that phytoceramide has a possible therapeutic role in managing cognitive impairment associated with Alzheimer's disease. The underlying mechanism might involve inhibition of p-tau formation via anti-apoptosis and anti-inflammation activity and promotion of PI3K/Akt/CREB signaling process.

Keywords: Alzheimer’s disease; Memory impairment; Neuroprotection; Phytoceramide; β-amyloid protein (25–35).

MeSH terms

  • Amyloid beta-Peptides / administration & dosage
  • Amyloid beta-Peptides / antagonists & inhibitors*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Cell Death / drug effects
  • Ceramides / administration & dosage
  • Ceramides / pharmacology*
  • Dose-Response Relationship, Drug
  • Male
  • Memory Disorders / chemically induced
  • Memory Disorders / drug therapy*
  • Mice
  • Mice, Inbred ICR
  • Neurons / drug effects*
  • Neurons / pathology
  • Oxidative Stress / drug effects
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / antagonists & inhibitors*
  • Peptide Fragments / metabolism
  • Structure-Activity Relationship

Substances

  • Amyloid beta-Peptides
  • Ceramides
  • Peptide Fragments
  • amyloid beta-protein (25-35)